INSILENS, A Noetera Company Biotech Intelligence Platform Turn Global Biotech Signals, Into Strategic Intelligence Explore with us Biotech Signals. Structured for Decisions. INSILENS converts global biotech activity into decision-grade intelligence for investors, executives, and business development teams. Deals and Financing ❮ Lilly + Ascidian – $1.9B RNA Exon Editing Deal June 3, 2026 YolTech – In Vivo CRISPR/Base Editing Platform Financing May 28, 2026 Waypoint Bio – China IIT CAR-T Strategy May 27, 2026 BMS – Anthropic AI Partnership May 20, 2026 ❯ Therapeutic Indication ❮ Karyopharm – SENTRY Phase 3 Full Data in Frontline Myelofibrosis June 2, 2026 Kelonia Therapeutics – In Vivo CAR-T Clinical Update June 1, 2026 TUNE-401 Epigenetic Silencing Clinical PoC June 1, 2026 Karyopharm – SENTRY Phase 3 Myelofibrosis Readout Watch June 1, 2026 ❯ Technology Modalities ❮ Regeneron – Gene Therapy Approved for Hearing Loss April 24, 2026 Cartherics – CAR-NK Manufacturing Expansion April 15, 2026 Life Biosciences – $80M Gene Therapy Financing April 9, 2026 Orca Bio – FDA Extends Orca-T Review Timeline April 9, 2026 ❯ View all